Skip to main content

Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · IEX Real-Time Price · USD
5.26 0.05 (0.96%)
Oct 26, 2021 1:40 PM EDT - Market open
Market Cap752.71M
Revenue (ttm)7.09M
Net Income (ttm)38.08M
Shares Out144.45M
EPS (ttm)0.29
PE Ratio17.95
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume178,686
Open5.25
Previous Close5.21
Day's Range5.18 - 5.32
52-Week Range1.03 - 9.65
Beta1.45
AnalystsHold
Price Target13.00 (+147.1%)
Earnings DateNov 4, 2021

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain; and LX2761. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and ...

IndustryBiotechnology
IPO DateApr 7, 2000
Employees78
Stock ExchangeNASDAQ
Ticker SymbolLXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for LXRX stock is "Hold." The 12-month stock price forecast is 13.00, which is an increase of 147.15% from the latest price.

Price Target
$13.00
(147.15% upside)
Analyst Consensus: Hold

News

6 Penny Stocks To Buy According To Analysts, Targets Up To 322%

Analysts are bullish on these penny stocks, are you? The post 6 Penny Stocks To Buy According To Analysts, Targets Up To 322% appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...

Other symbols:MDVLSWNVEONXELA
1 month ago - PennyStocks

Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care

New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure.

1 month ago - GlobeNewsWire

Lexicon Touts Analyses From Two Phase 3 Trials Of Its Heart Failure Drug

Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) has presented additional analyses from SOLOIST and SCORED Phase 3 trials evaluating heart failure candidate sotagliflozin, a dual SGLT1 & SGLT2 inhibitor. Data...

2 months ago - Benzinga

Lexicon's Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results fro...

Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 - The Digital Experience, including:

2 months ago - GlobeNewsWire

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 18.75% and 680.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Lexicon Pharmaceuticals: Q2 Earnings Insights

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 80.00% over the past year to ($0.13), which beat the es...

2 months ago - Benzinga

Craig Granowitz, M.D., Ph.D. Joins Lexicon as Senior Vice President and Chief Medical Officer

THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and...

2 months ago - GlobeNewsWire

Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update

Conference Call and Webcast at 8:00 am Eastern Time Conference Call and Webcast at 8:00 am Eastern Time

2 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Host Second Quarter 2021 Financial Results Conference Call and Webcast on July 30, 2021

THE WOODLANDS, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2021 financial results on Friday, July 30, 2021 before the markets o...

2 months ago - GlobeNewsWire

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q2 Earnings? What You Should Know

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Lexicon Pharmaceuticals Announces Symposium at the American Diabetes Association 81st Scientific Sessions

THE WOODLANDS, Texas, June 25, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video questi...

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals to Participate in the 2021 Jefferies Virtual Healthcare Conference

THE WOODLANDS, Texas, May 26, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon's president and chief executive officer, will present at th...

4 months ago - GlobeNewsWire

Lexicon Pharmaceuticals Announces Two Presentations at the American College of Cardiology's 70th Annual Scientific Se...

THE WOODLANDS, Texas, May 13, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be two virtual presentations highlighting sotagliflozin during the America...

5 months ago - GlobeNewsWire

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 11.76% and -99.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Lexicon Pharmaceuticals to Host First Quarter 2021 Financial Results Conference Call and Webcast on May 6, 2021

THE WOODLANDS, Texas, April 29, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2021 financial results on Thursday, May 6, 2021 after the markets cl...

5 months ago - GlobeNewsWire

Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Lexicon Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

THE WOODLANDS, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon's executive vice president, corporate and administrati...

6 months ago - GlobeNewsWire

Implied Volatility Surging for Lexicon Pharmaceuticals (LXRX) Stock Options

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 82.14% and 15.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Clinical Update

Conference Call and Webcast at 5:00 pm Eastern Time Conference Call and Webcast at 5:00 pm Eastern Time

7 months ago - GlobeNewsWire

Earnings Preview: Lexicon Pharmaceuticals

On Wednesday, March 10, Lexicon Pharmaceuticals (NASDAQ:LXRX) will release its latest earnings report. Benzinga's outlook for Lexicon Pharmaceuticals is included in the following report.

7 months ago - Benzinga

Will Lexicon Pharmaceuticals (LXRX) Report Negative Q4 Earnings? What You Should Know

Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

Other symbols:ADMAAVIRBNTXMRNA
8 months ago - Zacks Investment Research

Should You Buy Lexicon Pharmaceuticals Stock?

Your portfolio could benefit from its group of soon-to-be-commercialized drugs.

8 months ago - The Motley Fool

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls

With the trading day practically over, the broad markets were sliding into the weekend.

8 months ago - 24/7 Wall Street